search icon
      blog search icon

      Here’s to why Theratechnologies Inc. (THTX) stock surged during after-hours? - Stocks Telegraph

      By Mahnoor Shah

      Published on

      September 24, 2021

      7:30 AM UTC

      Here’s to why Theratechnologies Inc. (THTX) stock surged during after-hours? - Stocks Telegraph

      Theratechnologies Inc. (NASDAQ: (THTX) stock gained by 7.2% at last close while the THTX stock soars as high as 4.73% in the after-hours trading session. Theratechnologies is a pharmaceutical business that specializes in the discovery and marketing of novel treatments for unmet medical needs.

      THTX stock’ Current Update

      A research testing an intravenous (IV) push mode of administration of Trogarzo for the cure of Human immunodeficiency virus type 1 (HIV-1) infection showed consistent and highly significant results, according to Theratechnologies. There was no change in pharmacokinetics (PK) between IV Push and IV Infusion, according to the findings. A supplemental Biologics License Application (sBLA) is planned to be submitted to the FDA in the fourth quarter of 2021 based on these findings.

      The TMB-302 study was performed by the Company’s partner, TaiMed Biologics (TaiMed). They wanted to insure the adequacy and comparability of the existing Trogarzo IV treatment modality with a more convenient IV Push form of administration. It can be injected in 30 seconds without dilution versus the original IV Infusion’s 15-minute infusion time.

      Furthermore,

      As part of the TMB-302 research, Theratechnologies and TaiMed are now studying an intramuscular (IM) route of administration for Trogarzo, with patient testing, scheduled for the fourth quarter of 2021. Theratechnologies will lead and fund the research, with help from TaiMed. Theratechnologies is allowed to market the novel IV Push and IM methods of administration of Trogarzo under the conditions of the contract with TaiMed, if and when they are authorized.

      Paul Levesque, President and CEO of Theratechnologies,

      These findings show that the IV Push technique of Trogarzo administration is a viable alternative to the existing IV Infusion approach. Patients benefit from a faster infusion time with this more efficient IV Push form of administration, which only takes two short infusions each month. They are optimistic that the quicker infusion will improve patient cooperation, enables patients to benefit from long-acting antiretroviral treatment when Trogarzo is combined with other antiretrovirals.

      More From Stocks telegraph